This could explain the high accuracy obtained from the HER2‐driven morphometric signature model in predicting the response of HER2‐positive BC patients to HER2 pathway targeting therapy, superseding the HER2 IHC score‐based risk of recurrence model. The gene discussed is ERBB2; the disease is breast cancer.